Genequine Biotherapeutics, a Germany-based genetic medicine company based on research at Baylor College of Medicine, sold one of its treatments to pharmaceutical firm Flexion Therapeutics yesterday in deal worth up to $64m.
Flexion will pay an undisclosed sum up front for the rights to Genequine’s newly-rebranded FX201 osteoarthritis treatment, which is in pre-clinical development. Further payments could be due on certain development and regulatory milestones.
Founded in 2012, Genequine has developed a gene therapy for severe osteoarthritis of the knee. The…
